Although gene fusions occur rarely in non-small-cell lung cancer (NSCLC) patients, they represent a relevant target in treatment decision algorithms. To date, immunohistochemistry and fluorescence in situ hybridization are the two principal methods used in clinical trials. However, using these methods in routine clinical practice is often impractical and time consuming because they can only analyze single genes and the quantity of tissue material is often insufficient. Thus, novel technologies, able to test multiple genes in a single run with minimal sample input, are being under investigation. Here, we discuss the utility of next-generation sequencing and nCounter technologies in detecting simultaneous gene fusions in NSCLC patients.

Keywords:

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 71, 7–33 (2021).
MedlineGoogle Scholar
2. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009).
Medline CASGoogle Scholar
3. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase III trial. Lancet Oncol. 13, 239–246 (2012).
Medline CASGoogle Scholar
4. Yang JC, Wu YL, Schuler M et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, Phase III trials. Lancet Oncol. 16, 141–151 (2015).
Medline CASGoogle Scholar
5. Soria JC, Ohe Y, Vansteenkiste J et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113–125 (2018).
Medline CASGoogle Scholar
6. Varella-Garcia M. Chromosomal and genomic changes in lung cancer. Cell Adh Migr. 4, 100–106 (2010).
MedlineGoogle Scholar
7. Lindeman NI, Cagle PT, Aisner DL et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch. Pathol. Lab. Med. 142, 321–346 (2018).
Medline CASGoogle Scholar
8. Schram AM, Chang MT, Jonsson P, Drilon A. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat. Rev. Clin. Oncol. 14, 735–748 (2017).
Medline CASGoogle Scholar
9. Chmielecki J, Peifer M, Jia P et al. Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Res. 38, 6985–6996 (2010).
Medline CASGoogle Scholar
10. Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma. PLoS ONE 3, e1965 (2008).
MedlineGoogle Scholar
11. Selvanathan SP, Graham GT, Erkizan HV et al. Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing. Proc. Natl. Acad. Sci. USA 112, E1307–1316 (2015).
Medline CASGoogle Scholar
12. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 339, 1546–1558 (2013).
Medline CASGoogle Scholar
13. Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM. Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med. 7, 129 (2015).
MedlineGoogle Scholar
14. Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA et al. Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: a worldwide ring trial study on quantitative cytological molecular reference specimens. Cancer Cytopathol. 125, 615–626 (2017).
Medline CASGoogle Scholar
15. Pisapia P, Malapelle U, Roma G et al. Consistency and reproducibility of next-generation sequencing in cytopathology: a second worldwide ring trial study on improved cytological molecular reference specimens. Cancer Cytopathol. 127, 285–296 (2019).
Medline CASGoogle Scholar
16. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561–566 (2007).
Medline CASGoogle Scholar
17. Pan Y, Zhang Y, Li Y et al. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer 84, 121–126 (2014).
MedlineGoogle Scholar
18. Pisapia P, Lozano MD, Vigliar E et al. ALK and ROS1 testing on lung cancer cytologic samples: perspectives. Cancer Cytopathol. 125, 817–830 (2017).
Medline CASGoogle Scholar
19. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).
Medline CASGoogle Scholar
20. Du X, Shao Y, Qin HF, Tai YH, Gao HJ. ALK-rearrangement in non-small-cell lung cancer (NSCLC). Thorac Cancer 9, 423–430 (2018).
Medline CASGoogle Scholar
21. Shaw AT, Kim DW, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385–2394 (2013).
Medline CASGoogle Scholar
22. Solomon BJ, Mok T, Kim DW et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 371, 2167–2177 (2014).
Medline CASGoogle Scholar
23. Peters S, Camidge DR, Shaw AT et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377, 829–838 (2017).
Medline CASGoogle Scholar
24. Hida T, Nokihara H, Kondo M et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised Phase III trial. Lancet 390, 29–39 (2017).
Medline CASGoogle Scholar
25. Soria JC, Tan DSW, Chiari R et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, Phase III study. Lancet 389, 917–929 (2017).
Medline CASGoogle Scholar
26. Hida T, Nokihara H, Kondo M et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised Phase III trial. Lancet 390, 29–39 (2017).
Medline CASGoogle Scholar
27. Peters S, Camidge DR, Shaw AT et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377, 829–838 (2017).
Medline CASGoogle Scholar
28. Shaw AT, Bauer TM, de Marinis F et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N. Engl. J. Med. 383, 2018–2029 (2020).
Medline CASGoogle Scholar
29. Camidge DR, Kim DW, Tiseo M et al. Exploratory analysis of Brigatinib activity in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer and brain metastases in two clinical trials. J. Clin. Oncol. 36, 2693–2701 (2018).
Medline CASGoogle Scholar
30. Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190–1203 (2007).
Medline CASGoogle Scholar
31. Lin JJ, Shaw AT. Recent advances in targeting ROS1 in lung cancer. J. Thorac Oncol. 12, 1611–1625 (2017).
MedlineGoogle Scholar
32. Savic S, Rothschild S, Bubendorf L. Lonely driver ROS1. J. Thorac. Oncol. 12, 776–777 (2017).
MedlineGoogle Scholar
33. Shaw AT, Ou SH, Bang YJ et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N. Engl. J. Med. 371, 1963–1971 (2014).
Medline CASGoogle Scholar
34. Drilon A, Siena S, Ou SI et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two Phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 7, 400–409 (2017).
Medline CASGoogle Scholar
35. Bubendorf L, Büttner R, Al-Dayel F et al. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch. 469, 489–503 (2016).
Medline CASGoogle Scholar
36. Wu S, Wang J, Zhou L et al. Clinicopathological characteristics and outcomes of ROS1-rearranged patients with lung adenocarcinoma without EGFR, KRAS mutations and ALK rearrangements. Thorac. Cancer 6, 413–420 (2015).
Medline CASGoogle Scholar
37. Zhao J, Zheng J, Kong M, Zhou J, Ding W, Zhou J. Advanced lung adenocarcinomas with ROS1-rearrangement frequently show hepatoid cell. Oncotarget 7, 74162–74170 (2016).
MedlineGoogle Scholar
38. Kohno T, Ichikawa H, Totoki Y et al. KIF5B-RET fusions in lung adenocarcinoma. Nat. Med. 18, 375–377 (2012).
Medline CASGoogle Scholar
39. Li AY, McCusker MG, Russo A et al. RET fusions in solid tumors. Cancer Treat. Rev. 81, 101911 (2019).
MedlineGoogle Scholar
40. Mendoza L. Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: update. Oncol. Rev. 12, 352 (2018).
MedlineGoogle Scholar
41. Lipson D, Capelletti M, Yelensky R et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18, 382–384 (2012).
Medline CASGoogle Scholar
42. Drilon A, Rekhtman N, Arcila M et al. Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, Phase II, single-arm trial. Lancet Oncol. 17, 1653–1660 (2016).
Medline CASGoogle Scholar
43. American Association for Cancer Research. First RET Inhibitor on Path to FDA Approval. Cancer Discov. 9(11), 1476–1477 (2019).
Google Scholar
44. Drilon A, Oxnard GR, Tan DSW et al. Efficacy of Selpercatinib in RET fusion-positive non-small-cell lung cancer. N. Engl. J. Med. 383, 813–824 (2020).
Medline CASGoogle Scholar
45. Gainor JF, Curigliano G, Kim DW et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, Phase 1/2 study. Lancet Oncol. 22, 959–969 (2021).
Medline CASGoogle Scholar
46. Vaishnavi A, Capelletti M, Le AT et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat. Med. 19, 1469–1472 (2013).
Medline CASGoogle Scholar
47. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat. Commun. 5, 4846 (2014).
Medline CASGoogle Scholar
48. Harada T, Yatabe Y, Takeshita M et al. Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin. Cancer Res. 17, 2638–2645 (2011).
Medline CASGoogle Scholar
49. Marchetti A, Felicioni L, Pelosi G et al. Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum. Mutat. 29, 609–616 (2008).
Medline CASGoogle Scholar
50. Farago AF, Taylor MS, Doebele RC et al. Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion. JCO Precis Oncol. 2018, (2018).
Google Scholar
51. Drilon A, Laetsch TW, Kummar S et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl. J. Med. 378, 731–739 (2018).
Medline CASGoogle Scholar
52. Entrectinib effective across NTRK fusion-positive cancers. Cancer Discov. 9, OF4 2019.
Google Scholar
53. TRK Inhibitor Shows Early Promise. Cancer Discov. 6, OF4 (2016).
Google Scholar
54. Fernandez-Cuesta L, Plenker D, Osada H et al. CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov. 4, 415–422 (2014).
Medline CASGoogle Scholar
55. Jonna S, Feldman RA, Swensen J et al. Detection of NRG1 gene fusions in solid tumors. Clin. Cancer Res. 25, 4966–4972 (2019).
Medline CASGoogle Scholar
56. Muscarella LA, Rossi A. NRG1: a cinderella fusion in lung cancer? Lung Cancer Manag. 6, 121–123 (2017).
CASGoogle Scholar
57. Muscarella LA, Trombetta D, Fabrizio FP et al. ALK and NRG1 fusions coexist in a patient with signet ring cell lung adenocarcinoma. J. Thorac. Oncol. 12, e161–e163 (2017).
MedlineGoogle Scholar
58. Trombetta D, Graziano P, Scarpa A et al. Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression. Oncotarget 9, 9661–9671 (2018).
MedlineGoogle Scholar
59. Shin DH, Lee D, Hong DW et al. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. Oncotarget 7, 69450–69465 (2016).
MedlineGoogle Scholar
60. Jones MR, Lim H, Shen Y et al. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer. Ann. Oncol. 28, 3092–3097 (2017).
Medline CASGoogle Scholar
61. Gay ND, Wang Y, Beadling C et al. Durable response to afatinib in lung adenocarcinoma harboring NRG1 gene fusions. J. Thorac. Oncol. 12, e107–e110 (2017).
MedlineGoogle Scholar
62. Jang JS, Lee A, Li J et al. Common oncogene mutations and novel SND1-BRAF transcript fusion in lung adenocarcinoma from never smokers. Sci. Rep. 5, 9755 (2015).
Medline CASGoogle Scholar
63. Ross JS, Wang K, Chmielecki J et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int. J. Cancer 138, 881–890 (2016).
Medline CASGoogle Scholar
64. Zhu YC, Wang WX, Xu CW et al. A patient with lung adenocarcinoma with BRAF gene fusion and response to vemurafenib. Clin. Lung Cancer 20, e224–e228 (2019).
MedlineGoogle Scholar
65. Conde E, Hernandez S, Prieto M, Martinez R, Lopez-Rios F. Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas. Expert Rev. Mol. Diagn. 16, 707–713 (2016).
Medline CASGoogle Scholar
66. Frampton GM, Fichtenholtz A, Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31, 1023–1031 (2013).
Medline CASGoogle Scholar
67. Smuk G, Pajor G, Szuhai K et al. Attenuated isolated 3′ signal: a highly challenging therapy relevant ALK FISH pattern in NSCLC. Lung Cancer 143, 80–85 (2020).
MedlineGoogle Scholar
68. Viñal D, Martínez D, Higuera O, de Castro J. Genomic profiling in non-small-cell lung cancer in young patients. A systematic review. ESMO Open 6, 100045 (2021).
Medline CASGoogle Scholar
69. Sholl LM, Sun H, Butaney M et al. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am. J. Surg. Pathol. 37, 1441–1449 (2013).
MedlineGoogle Scholar
70. Hechtman JF, Benayed R, Hyman DM et al. Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am. J. Surg. Pathol. 41, 1547–1551 (2017).
MedlineGoogle Scholar
71. Vigliar E, Malapelle U, de Luca C, Bellevicine C, Troncone G. Challenges and opportunities of next-generation sequencing: a cytopathologist's perspective. Cytopathology 26, 271–283 (2015).
Medline CASGoogle Scholar
72. Sgariglia R, Pisapia P, Nacchio M et al. Multiplex digital colour-coded barcode technology on RNA extracted from routine cytological samples of patients with non-small cell lung cancer: pilot study. J. Clin. Pathol. 70, 803–806 (2017).
Medline CASGoogle Scholar
73. Malapelle U, Mayo de-Las-Casas C, Rocco D et al. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients. Br. J. Cancer 116, 802–810 (2017).
Medline CASGoogle Scholar
74. Rothberg JM, Hinz W, Rearick TM et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature 475, 348–352 (2011).
Medline CASGoogle Scholar
75. Lira ME, Kim TM, Huang D et al. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J. Mol. Diagn. 15, 51–61 (2013).
Medline CASGoogle Scholar
76. Evangelista AF, Zanon MF, Carloni AC et al. Detection of ALK fusion transcripts in FFPE lung cancer samples by NanoString technology. BMC Pulm. Med. 17, 86 (2017).
MedlineGoogle Scholar
77. Reguart N, Teixidó C, Giménez-Capitán A et al. Identification of ALK, ROS1, and RET fusions by a multiplexed mRNA-based assay in formalin-fixed, paraffin-embedded samples from advanced non-small-cell lung cancer patients. Clin. Chem. 63, 751–760 (2017).
Medline CASGoogle Scholar
78. Rogers TM, Arnau GM, Ryland GL et al. Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. Sci Rep. 7, 42259 (2017).
Medline CASGoogle Scholar
79. Lira ME, Choi YL, Lim SM et al. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. J. Mol. Diagn. 16, 229–243 (2014).
Medline CASGoogle Scholar
80. Alì G, Bruno R, Savino M et al. Analysis of fusion genes by NanoString system: a role in lung cytology? Arch. Pathol. Lab. Med. 142, 480–489 (2018).
Medline CASGoogle Scholar
81. Lin C, Shi X, Yang S et al. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer. Lung Cancer 131, 62–68 (2019).
MedlineGoogle Scholar
82. Ji X, Che N, Lin R, Chen J, Wu X. Efficient ten-gene analysis of NSCLC tissue samples by next-generation sequencing. Pathol. Res. Pract. 215, 1066–1070 (2019).
Medline CASGoogle Scholar
83. Zhao R, Zhang J, Han Y et al. Clinicopathological features of ALK expression in 9889 cases of non-small-cell lung cancer and genomic rearrangements identified by capture-based next-generation sequencing: a chinese retrospective analysis. Mol. Diagn. Ther. 23(3), 395–405 (2019).
Medline CASGoogle Scholar
84. Dacic S, Villaruz LC, Abberbock S, Mahaffey A, Incharoen P, Nikiforova MN. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma. Oncotarget 7, 82943–82952 (2016).
MedlineGoogle Scholar
85. McLeer-Florin A, Duruisseaux M, Pinsolle J et al. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer. Lung Cancer 116, 15–24 (2018).
MedlineGoogle Scholar
86. Letovanec I, Finn S, Zygoura P et al. Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: results from the European Thoracic Oncology Platform Lungscape Project. J. Thorac. Oncol. 13, 413–425 (2018).
Medline CASGoogle Scholar
87. Vendrell JA, Taviaux S, Béganton B et al. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. Sci Rep. 7, 12510 (2017).
MedlineGoogle Scholar
88. Marchetti A, Pace MV, Di Lorito A et al. Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: comparison with FISH, immunohistochemistry and next generation sequencing assays. Lung Cancer 99, 11–16 (2016).
MedlineGoogle Scholar
89. Reclusa P, Laes JF, Malapelle U et al. EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy. Transl. Cancer Res. 8(Suppl. 1), S76–S78 (2019).
CASGoogle Scholar
90. Guibert N, Hu Y, Feeney N et al. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. Ann. Oncol. 29, 1049–1055 (2018).
Medline CASGoogle Scholar
91. Scattone A, Catino A, Schirosi L et al. Discordance between FISH, IHC, and NGS analysis of ALK status in advanced non-small cell lung cancer (NSCLC): a brief report of 7 cases. Transl. Oncol. 12, 389–395 (2019).
MedlineGoogle Scholar
92. Fumagalli C, Catania C, Ranghiero A et al. Molecular profile of advanced non-small cell lung cancers in octogenarians: the door to precision medicine in elderly patients. J. Clin. Med. 8(1), 112 (2019).
CASGoogle Scholar
93. Clavé S, Rodon N, Pijuan L et al. Next-generation sequencing for ALK and ROS1 rearrangement detection in patients with non-small-cell lung cancer: implications of FISH-positive patterns. Clin. Lung Cancer 20(4), e421–e429( 2019).
Medline CASGoogle Scholar
94. Park S, Ahn BC, Lim SW et al. Characteristics and outcome of ROS1-positive non-small cell lung cancer patients in routine clinical practice. J. Thorac. Oncol. 13, 1373–1382 (2018).
MedlineGoogle Scholar
95. Lin JJ, Ritterhouse LL, Ali SM et al. ROS1 fusions rarely overlap with other oncogenic drivers in non-small cell lung cancer. J. Thorac. Oncol. 12, 872–877 (2017).
MedlineGoogle Scholar
96. Davies KD, Le AT, Sheren J et al. Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples. J. Thorac. Oncol. 13, 1474–1482 (2018).
MedlineGoogle Scholar
97. Lindquist KE, Karlsson A, Levéen P et al. Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer. Oncotarget 8, 34796–34810 (2017).
MedlineGoogle Scholar
98. Karlsson A, Cirenajwis H, Ericson-Lindquist K et al. A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer. Sci Rep. 9, 5207 (2019).
MedlineGoogle Scholar
99. Tsoulos N, Papadopoulou E, Metaxa-Mariatou V et al. Tumor molecular profiling of NSCLC patients using next generation sequencing. Oncol. Rep. 38, 3419–3429 (2017).
Medline CASGoogle Scholar
100. Song Z, Yu X, Zhang Y. Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma. Lung Cancer 101, 16–21 (2016).
MedlineGoogle Scholar
101. Velizheva NP, Rechsteiner MP, Valtcheva N et al. Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study. Pathol. Res. Pract. 214, 572–578 (2018).
Medline CASGoogle Scholar
102. Vaughn CP, Costa JL, Feilotter HE et al. Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. BMC Cancer 18, 828 (2018).
MedlineGoogle Scholar
103. Penault-Llorca F, Rudzinski ER, Sepulveda AR. Testing algorithm for identification of patients with TRK fusion cancer. J. Clin. Pathol. 72(7), 460–467 (2019).
Medline CASGoogle Scholar
104. Vaishnavi A, Capelletti M, Le AT et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat. Med. 19, 1469–1472 (2013).
Medline CASGoogle Scholar
105. Farago AF, Taylor MS, Doebele RC et al. Clinicopathologic features of non-small-cell lung cancer harboring an NTRK Gene Fusion. JCO Precis Oncol. 2018, (2018).
Google Scholar
106. Dhanasekaran SM, Balbin OA, Chen G et al. Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat. Commun. 5, 5893 (2014).
Medline CASGoogle Scholar
107. Drilon A, Somwar R, Mangatt BP et al. Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers. Cancer Discov. 8, 686–695 (2018).
Medline CASGoogle Scholar
108. Plenker D, Bertrand M, de Langen AJ et al. Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients. Clin. Cancer Res. 24, 1337–1343 (2018).
Medline CASGoogle Scholar
109. Sholl LM, Sun H, Butaney M et al. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. Am. J. Surg. Pathol. 37, 1441–1449 (2013).
MedlineGoogle Scholar
110. Lee SE, Lee B, Hong M et al. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Mod. Pathol. 28, 468–479 (2015).
Medline CASGoogle Scholar
111. Hirsch FR, McElhinny A, Stanforth D et al. PD-L1 immunohistochemistry assays for lung cancer: results from Phase I of the blueprint PD-L1 IHC assay comparison project. J. Thorac. Oncol. 12, 208–222 (2017).
MedlineGoogle Scholar
112. Tsao MS, Kerr KM, Kockx M et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint Phase 2 project. J. Thorac. Oncol. 13, 1302–1311 (2018).
MedlineGoogle Scholar
113. Leighl NB, Page RD, Raymond VM et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin. Cancer Res. 25, 4691–4700 (2019).
Medline CASGoogle Scholar
114. Aggarwal C, Thompson JC, Black TA et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 5, 173–180 (2019).
MedlineGoogle Scholar
115. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 294, 853–858 (2001).
Medline CASGoogle Scholar
116. Nicolè L, Cappello F, Cappellesso R, VandenBussche CJ, Fassina A. MicroRNA profiling in serous cavity specimens: diagnostic challenges and new opportunities. Cancer Cytopathol. 127, 493–500 (2019).
MedlineGoogle Scholar
117. Simonato F, Ventura L, Sartori N et al. Detection of microRNAs in archival cytology urine smears. PLoS ONE 8, e57490 (2013).
Medline CASGoogle Scholar
118. Rossi ED, Bizzarro T, Martini M et al. The evaluation of miRNAs on thyroid FNAC: the promising role of miR-375 in follicular neoplasms. Endocrine 54, 723–732 (2016).
Medline CASGoogle Scholar
119. Gasparini P, Cascione L, Landi L et al. microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers. Proc. Natl Acad. Sci. USA 112, 14924–14929 (2015).
Medline CASGoogle Scholar
120. Kim H, Yang JM, Jin Y et al. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status. Oncotarget 8, 8484–8498 (2017).
MedlineGoogle Scholar
121. De Luca C, Pepe F, Iaccarino A et al. RNA-based assay for next-generation sequencing of clinically relevant gene fusions in non-small cell lung cancer. Cancers (Basel) 13, 139 (2021).
Google Scholar

Vol. 22, No. 13

Metrics

Downloaded 324 times

History

Received 21 April 2021

Accepted 26 July 2021

Published online 16 September 2021

Published in print August 2021

Information

Keywords

Author contributions

P Pisapia, U Malapelle and G Troncone conceived the review. All authors collected the literature data, wrote the original draft and approved the final version of the manuscript.

Acknowledgments

The authors thank P Merolla for editing the manuscript.

Financial & competing interests disclosure

E Vigliar has received personal fees (as consultant and/or speaker bureau) from Diaceutics, unrelated to the current work. U Malapelle has received personal fees (as consultant and/or speaker bureau) from Boehringer Ingelheim, Roche, MSD, Amgen, Thermo Fisher Scientifics, Eli Lilly, Diaceutics, GSK, Merck and AstraZeneca, unrelated to the current work. G Troncone reports personal fees (as speaker bureau or advisor) from Roche, MSD, Pfizer and Bayer, unrelated to the current work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download

Methods for actionable gene fusion detection in lung cancer: now and in the future

Abstract

References